The Small Molecule Innovator CDMO Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Small Molecule Innovator CDMO Market:
https://www.thebusinessresearchcompany.com/report/small-molecule-innovator-cdmo-global-market-report
According to The Business Research Company’s Small Molecule Innovator CDMO Global Market Report 2024, The small molecule innovator cdmo market size has grown strongly in recent years. It will grow from $51.84 billion in 2023 to $56.13 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising demand for outsourcing, increasing complexity of small molecule drugs, increasing focus on time-to-market, cost pressures on pharma companies, stringent regulatory requirements.
The small molecule innovator cdmo market size is expected to see strong growth in the next few years. It will grow to $76.46 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to rise in personalized medicine and targeted therapies, increased focus on green chemistry and sustainability, demand for faster time-to-market for new drugs, expansion of biopharmaceutical pipeline, emergence of advanced therapies. Major trends in the forecast period include rise of virtual and remote development models, increased collaboration and partnerships in the pharma industry, expansion of cdmo services to emerging markets, utilization of single-use technologies in manufacturing, evolution of cdmos into strategic development partners.
The rising prevalence of chronic diseases is expected to propel the growth of the small-molecule innovator CDMO market going forward. Chronic diseases are diseases that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Small molecule innovator CDMO provides services and manufactures chronic disease medicines for pharmaceutical and biotech companies. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that in the US by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the rising prevalence of chronic diseases is propelling the small-molecule innovator CDMO market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12178&type=smp
The small molecule innovator cdmo market covered in this report is segmented –
1) By Product: Small Molecule Active Pharmaceutical Ingredient(API), Small Molecule Drug Product
2) By Stage: Preclinical, Clinical, Commercial
3) By Therapeutic: Cardiovascular Disease, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Disease, Other Therapeutics
4) By Customer: Pharmaceutical, Biotechnology
Product innovations are a key trend gaining popularity in the small molecule CDMO market. Major companies operating in the small-molecule innovator CDMO market are adopting new innovative products to sustain their position in the market. For instance, in May 2023, Oxford Biomedica, a UK-based company, launched TetraVecta, the next-generation system for CDMO. Small-molecule innovator enterprises can overcome prior difficulties in medicinal development due to the payload’s size, complexity, or interference to be delivered. Furthermore, the TetraVecta technology helps accelerate the development and implementation of in vivo gene treatments.
The small molecule innovator cdmo market report table of contents includes:
.
.
.
Top Major Players :
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Plasma powder is a protein-rich ingredient derived from the spray-drying of plasma,…
Overview and Scope A pedestrian bridge is a constructed framework spanning a railway, river, or…
Overview and Scope Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic…
Overview and Scope A neurological biomarker is a substance that provides objective and quantifiable information…
Overview and Scope Home insurance is a policy that pays for expenses and damage to…
Overview and Scope Extended-release drugs are a dosage form made to release the medication over…